-
1Academic Journal
Authors: D. V. Semenov, R. V. Orlova, V. I. Shirokorad, S. V. Kostritsky, M. I. Gluzman, Yu. S. Korneva, Д. В. Семенов, Р. В. Орлова, В. И. Широкорад, С. В. Кострицкий, М. И. Глузман, Ю. С. Корнева
Source: Siberian journal of oncology; Том 23, № 1 (2024); 53-62 ; Сибирский онкологический журнал; Том 23, № 1 (2024); 53-62 ; 2312-3168 ; 1814-4861
Subject Terms: метастазэктомия, cytoreductive nephrectomy, metastasectomy, циторедуктивная нефрэктомия
File Description: application/pdf
Relation: https://www.siboncoj.ru/jour/article/view/2964/1202; Capitanio U., Bensalah K., Bex A., Boorjian S.A., Bray F., Coleman J., Gore J.L., Sun M., Wood C., Russo P. Epidemiology of Renal Cell Carcinoma. Eur Urol. 2019; 75(1): 74–84. doi:10.1016/j.eururo.2018.08.036.; Ljungberg B., Albiges L., Abu-Ghanem Y., Bensalah K., Dabestani S., Fernández-Pello S., Giles R.H., Hofmann F., Hora M., Kuczyk M.A., Kuusk T., Lam T.B., Marconi L., Merseburger A.S., Powles T., Staehler M., Tahbaz R., Volpe A., Bex A. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. Eur Urol. 2019; 75(5): 799–810. doi:10.1016/j.eururo.2019.02.011.; Culp S.H., Tannir N.M., Abel E.J., Margulis V., Tamboli P., Matin S.F., Wood C.G. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer. 2010; 116(14): 3378–88. doi:10.1002/cncr.25046.; Rini B.I., Dorff T.B., Elson P., Rodriguez C.S., Shepard D., Wood L., Humbert J., Pyle L., Wong Y.N., Finke J.H., Rayman P.A., Larkin J.M., Garcia J.A., Plimack E.R. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol. 2016; 17(9): 1317–24. doi:10.1016/S1470-2045(16)30196-6.; Méjean A., Ravaud A., Thezenas S., Colas S., Beauval J.B., Bensalah K., Geoffrois L., Thiery-Vuillemin A., Cormier L., Lang H., Guy L., Gravis G., Rolland F., Linassier C., Lechevallier E., Beisland C., Aitchison M., Oudard S., Patard J.J., Theodore C., Chevreau C., Laguerre B., Hubert J., Gross-Goupil M., Bernhard J.C., Albiges L., Timsit M.O., Lebret T., Escudier B. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. N Engl J Med. 2018; 379(5): 417–27. doi:10.1056/NEJMoa1803675.; Omid S., Abufaraj M., Remzi M. Metastasectomy in patients with renal cell carcinoma: when and how? Curr Opin Urol. 2020; 30(4): 602–9. doi:10.1097/MOU.0000000000000768.; Isali I., Braun A., Bukavina L., Psutka S.P. Role of cytoreductive surgery in the era of immunotherapy. Curr Opin Urol. 2022; 32(6): 618–26. doi:10.1097/MOU.0000000000001037.; Ciccarese C., Iacovelli R., Porta C., Procopio G., Bria E., Astore S., Cannella M.A., Tortora G. Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis. Cancer Treat Rev. 2021; 100. doi:10.1016/j.ctrv.2021.102295.; Kim S.H., Suh Y.S., Lee D.E., Park B., Joo J., Joung J.Y., Seo H.K., Lee K.H., Chung J. A retrospective comparative study of progression-free survival and overall survival between metachronous and synchronous metastatic renal cell carcinoma in intermediate- or poor-risk patients treated with VEGF-targeted therapy. Oncotarget. 2017; 8(55): 93633–43. doi:10.18632/oncotarget.20674.; Courcier J., Dalban C., Laguerre B., Ladoire S., Barthélémy P., Oudard S., Joly F., Gravis G., Chevreau C., Geoffrois L., Deluche É., Rolland F., Topart D., Culine S., Négrier S., Mahammedi H., Tantot F., Jamet A., Escudier B., Flippot R., Albigès L. Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial. Eur Urol. 2021; 80(3): 325–9. doi:10.1016/j.eururo.2021.05.020.; Kato R., Naito S., Numakura K., Hatakeyama S., Koguchi T., Kojima T., Kawasaki Y., Kandori S., Kawamura S., Arai Y., Ito A., Nishiyama H., Kojima Y., Ohyama C., Habuchi T., Tsuchiya N., Obara W. Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era - a multi-institutional retrospective study. Int J Clin Oncol. 2022; 27(3): 563–73. doi:10.1007/s10147-021-02091-8. Erratum in: Int J Clin Oncol. 2023; 28(5): 726–7.; Dr Hall B., Abel E.J. The Evolving Role of Metastasectomy for Patients with Metastatic Renal Cell Carcinoma. Urol Clin North Am. 2020; 47(3): 379–88. doi:10.1016/j.ucl.2020.04.012.; Wu K., Liu Z., Shao Y., Li X. Nomogram Predicting Survival to Assist Decision-Making of Metastasectomy in Patients With Metastatic Renal Cell Carcinoma. Front Oncol. 2020; 10. doi:10.3389/fonc.2020.592243.; Verbiest A., Couchy G., Job S., Caruana L., Lerut E., Oyen R., de Reyniès A., Tosco L., Joniau S., Van Poppel H., Van Raemdonck D., Van Den Eynde K., Wozniak A., Zucman-Rossi J., Beuselinck B. Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy. Eur Urol. 2018; 74(4): 474–80. doi:10.1016/j.eururo.2018.01.042.; https://www.siboncoj.ru/jour/article/view/2964
-
2Academic Journal
Authors: D. V. Semenov, R. V. Orlova, V. I. Shirokorad, S. V. Kostritskiy, N. A. Karlova, Д. В. Семенов, Р. В. Орлова, В. И. Широкорад, С. В. Кострицкий, Н. А. Карлова
Source: Cancer Urology; Том 20, № 3 (2024); 22-32 ; Онкоурология; Том 20, № 3 (2024); 22-32 ; 1996-1812 ; 1726-9776
Subject Terms: системная терапия, циторедуктивная нефрэктомия, метастазэктомия, общая выживаемость, прогностическая группа
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1766/1571; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1766/1435; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1766/1436; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1766/1437; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1766/1438; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1766/1439; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1766/1440; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1766/1441; Capitanio U., Bensalah K., Bex A. et al. Epidemiology of renal cell carcinoma. Eur Urol 2019;75:74–84. DOI:10.1016/j.eururo.2018.08.036; Doppalapudi S.K., Leopold Z.R., Thaper A. et al. Clearing up clear cell: clarifying the immuno-oncology treatment landscape for metastatic clear cell RCC. Cancers (Basel) 2021;13(16):4140. DOI:10.3390/cancers13164140; Choi C.I., Kang M., Sung H.H. et al. Oncologic outcomes of cytoreductive nephrectomy in synchronous metastatic renal-cell carcinoma: a single-center experience. Clin Genitourin Cancer 2018;16(6):e1189–99. DOI:10.1016/j.clgc.2018.07.030; Omid S., Abufaraj M., Remzi M. Metastasectomy in patients with renal cell carcinoma: when and how? Curr Opin Urol 2020;30(4):602–9. DOI:10.1097/mou.0000000000000768; Prunty M., Bukavina L., Psutka S.P. Metastasectomy in kidney cancer: current indications and treatment approaches. Curr Opin Support Palliat Care 2021;15(4):266–75. DOI:10.1097/spc.0000000000000574; Zhao Y., Li J., Li C. et al. Prognostic factors for overall survival after lung metastasectomy in renal cell cancer patients: a systematic review and meta- analysis. Int J Surg 2017;41:70–7. DOI:10.1016/j.ijsu.2017.03.062; Ouzaid I., Capitanio U., Staehler M. et al. Surgical metastasectomy in renal cell carcinoma: a systematic review. Eur Urol Oncol 2019;2:141–9. DOI:10.1016/j.euo.2018.08.028; Russo P., Synder M., Vickers A. et al. Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer. Sci World J 2007;7:982931. DOI:10.1100/tswurol.2007.60; Dr Hall B., Abel E.J. The evolving role of metastasectomy for patients with metastatic renal cell carcinoma. Urol Clin North Am 2020;47(3):379–88. DOI:10.1016/j.ucl.2020.04.012; Sun M., Meyer C.P., Karam J.A. et al. Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. Eur J Surg Oncol 2018;44(9):1439–45. DOI:10.1016/j.ejso.2018.05.026; Dragomir A., Nazha S., Wood L.A. et al. Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: the Canadian Kidney Cancer information system experience. Urol Oncol 2020;38(10):799.e1–10. DOI:10.1016/j.urolonc.2020.07.021; Fares A.F., Araujo D.V., Calsavara V. et al. Complete metastasectomy in renal cell carcinoma: a propensity-score matched by the International Metastatic RCC Database Consortium prognostic model. Ecancermedicalscience 2019;13:967. DOI:10.3332/ecancer.2019.967; Wu K., Liu Z., Shao Y., Li X. Nomogram predicting survival to assist decision-making of metastasectomy in patients with metastatic renal cell carcinoma. Front Oncol 2020;10:592243. DOI:10.3389/fonc.2020.592243; Staehler M., Haseke N., Zilinberg E. et al. Complete remission achieved with angiogenic therapy in metastatic renal cell carcinoma including surgical intervention. Urol Oncol 2010;28(2):139–44. DOI:10.1016/j.urolonc.2009.03.033; Ishihara H., Takagi T., Kondo T. et al. Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era. Urol Oncol 2021;39(1):77.e17–25. DOI:10.1016/j.urolonc.2020.08.011; Kim S.H., Park W.S., Park B. et al. A retrospective analysis of the impact of metastasectomy on prognostic survival according to metastatic organs in patients with metastatic renal cell carcinoma. Front Oncol 2019;9:413. DOI:10.3389/fonc.2019.00413; Kato S., Demura S., Murakami H. et al. Clinical outcomes and prognostic factors following the surgical resection of renal cell carcinoma spinal metastases. Cancer Sci 2021;112(6):2416–25. DOI:10.1111/cas.14902; Langerhuizen D.W., Janssen S.J., van der Vliet Q.M. et al. Metastasectomy, intralesional resection, or stabilization only in the treatment of bone metastases from renal cell carcinoma. J Surg Oncol 2016;114(2):237–45. DOI:10.1002/jso.2428; https://oncourology.abvpress.ru/oncur/article/view/1766
-
3Academic Journal
Authors: М. И. Волкова, Д. А. Носов, Б. Я. Алексеев, О. А. Гладков, В. Б. Матвеев
Source: Malignant tumours; Том 14, № 3s2-2 (2024); 207-220 ; Злокачественные опухоли; Том 14, № 3s2-2 (2024); 207-220 ; 2587-6813 ; 2224-5057
Subject Terms: циторедуктивная нефрэктомия, иммунотерапия, ингибиторы m-TOR, тирозинкиназные ингибиторы
File Description: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/1389/994; https://www.malignanttumors.org/jour/article/view/1389
-
4Academic Journal
Authors: D. V. Semenov, R. V. Orlova, V. I. Shirokorad, S. V. Kostritskiy, M. I. Gluzman, Yu. S. Korneva, Д. В. Семенов, Р. В. Орлова, В. И. Широкорад, С. В. Кострицкий, М. И. Глузман, Ю. С. Корнева
Source: Cancer Urology; Том 19, № 3 (2023); 31-44 ; Онкоурология; Том 19, № 3 (2023); 31-44 ; 1996-1812 ; 1726-9776
Subject Terms: системная терапия, cytoreductive nephrectomy, overall survival, IMDC risk group, systemic therapy, циторедуктивная нефрэктомия, общая выживаемость, группа прогноза по IMDC
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1687/1477; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1687/1310; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1687/1311; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1687/1312; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1687/1313; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1687/1314; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1687/1315; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1687/1316; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1687/1317; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1687/1318; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1687/1319; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1687/1320; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1687/1321; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1687/1322; Capitanio U., Bensalah K., Bex A. et al. Epidemiology of renal cell carcinoma. Eur Urol 2019;75(1):74-84. DOI:10.1016/j.eururo.2018.08.036; Ljungberg B., Albiges L., Abu-Ghanem Y. et al. European Association of Urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol 2019;75(5):799-810. DOI:10.1016/j.eururo.2019.02.011; Flanigan R.C., Salmon S.E., Blumenstein B.A. et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345(23):1655-9. DOI:10.1056/NEJMoa003013; Mickisch G.H., Garin A., van Poppel H. et al. European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358(9286):966-70. DOI:10.1016/s0140-6736(01)06103-7; Flanigan R.C., Mickisch G., Sylvester R. et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171(3):1071-6. DOI:10.1097/01.ju.0000110610.61545.ae; Heng D.Y., Wells J.C., Rini B.I. et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 2014;66(4):704-10. DOI:10.1016/j.eururo.2014.05.034; Mejean A., Ravaud A., Thezenas S. et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med 2018;379(5):417-27. DOI:10.1056/NEJMoa1803675; Bex A., Mulders P., Jewett M. et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial. JAMA Oncol 2019;5(2):164-70. DOI:10.1001/jamaoncol.2018.5543; Motzer R.J., Jonasch E., Michaelson M.D. et al. NCCN Guidelines Insights: kidney cancer, version 2.2020. J Natl Compr Canc Netw 2019;17(11):1278-85. DOI:10.6004/jnccn.2019.0054; Xiao W.J., Zhu Y., Dai B. et al. Assessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: a SEER analysis. Int Braz J Urol 2015;41(2):288-95. DOI:10.1590/s1677-5538.IBJU.2015.02.15; Hanna N., Sun M., Meyer C.P. et al. Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: a National Cancer Data Base study. J Clin Oncol 2016;34(27):3267-75. DOI:10.1200/JCO.2016.66.7931; Arora S., Sood A., Dalela D. et al. Cytoreductive nephrectomy: assessing the generalizability of the CARMENA trial to real-world national cancer data base cases. Eur Urol 2019;75(2):352-3. DOI:10.1016/j.eururo.2018.10.054; Bhindi B., Abel E.J., Albiges L. et al. Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond: an individualized approach to metastatic renal cell carcinoma. Eur Urol 2019;75(1):111-28. DOI:10.1016/j.eururo.2018.09.016; Singla N., Hutchinson R.C., Ghandour R.A. et al. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: an analysis of the National Cancer Database. Urol Oncol 2020;38(6):604.e9-17. DOI:10.1016/j.urolonc.2020.02.029; I.N. Group SO. Comparing the outcome of immunotherapy-based drug combination therapy with or without surgery to remove the kidney in metastatic kidney cancer, the PROBE trial (PROBE).; Deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: The NORDIC-SUN-Trial (NORDIC-SUN). Sponsor: Donskov F., Aarhus University Hospital. DOI:10.31525/ct1-nct03977571; Mejean A., Ravaud A., Thezenas S. et al. Sunitinib alone or after nephrectomy for patients with metastatic renal cell carcinoma: is there still a role for cytoreductive nephrectomy? Eur Urol 2021;80(4):417-24. DOI:10.1016/j.eururo.2021.06.009; Kato R., Naito S., Numakura K. et al. Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era - a multi-institutional retrospective study. Int J Clin Oncol 2022;27(3):563-73. DOI:10.1007/s10147-021-02091-8; Esagian S.M., Ziogas I.A., Kosmidis D. et al. Long-term survival outcomes of cytoreductive nephrectomy combined with targeted therapy for metastatic renal cell carcinoma: a systematic review and individual patient data meta-analysis. Cancers (Basel) 2021;13(4):695. DOI:10.3390/cancers13040695; Bhindi B., Graham J., Wells J.C. et al. Deferred cytoreductive nephrectomy in patients with newly diagnosed metastatic renal cell carcinoma. Eur Urol 2020;78(4):615-23. DOI:10.1016/j.eururo.2020.04.038; De Bruijn R., Wimalasingham A., Szabados B. et al. Deferred cytoreductive nephrectomy following presurgical vascular endothelial growth factor receptor-targeted therapy in patients with primary metastatic clear cell renal cell carcinoma: a pooled analysis of prospective trial data. Eur Urol Oncol 2020;3(2):168-73. DOI:10.1016/j.euo.2019.12.004; Bakouny Z., El Zarif T., Dudani S. et al. Upfront cytoreductive nephrectomy for metastatic renal cell carcinoma treated with immune checkpoint inhibitors or targeted therapy: an observational study from the international metastatic renal cell carcinoma database consortium. Eur Urol 2022;83(2):145-51. DOI:10.1016/j.eururo.2022.10.004; Westerman M.E., Shapiro D.D., Tannir N.M. et al. Survival following cytoreductive nephrectomy: a comparison of existing prognostic models. BJU Int 2020;126(6):745-53. DOI:10.1111/bju.15160; Mori K., Quhal F., Yanagisawa T. et al. The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: a systematic review and meta-analysis. Int Immunopharmacol 2022;108:10872. DOI:10.1016/j.intimp.2022.108720; https://oncourology.abvpress.ru/oncur/article/view/1687
-
5Academic Journal
Authors: М. И. Волкова, Б. Я. Алексеев, О. А. Гладков, В. Б. Матвеев, Д. А. Носов
Source: Malignant tumours; Том 13, № 3s2-1 (2023); 609-619 ; Злокачественные опухоли; Том 13, № 3s2-1 (2023); 609-619 ; 2587-6813 ; 2224-5057
Subject Terms: циторедуктивная нефрэктомия, иммунотерапия, ингибиторы m-TOR, ингибиторы VEGFR
File Description: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/1233/867; https://www.malignanttumors.org/jour/article/view/1233
-
6Academic Journal
Authors: М. И. Волкова, Б. Я. Алексеев, О. А. Гладков, В. Б. Матвеев, Д. А. Носов
Source: Malignant tumours; Том 12, № 3s2-1 (2022); 579-588 ; Злокачественные опухоли; Том 12, № 3s2-1 (2022); 579-588 ; 2587-6813 ; 2224-5057
Subject Terms: циторедуктивная нефрэктомия, иммунотерапия, ингибиторы m-TOR, ингибиторы VEGF(R)
File Description: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/1050/746; https://www.malignanttumors.org/jour/article/view/1050
-
7Academic Journal
Authors: P. A. Karnaukh, П. А. Карнаух
Source: Cancer Urology; Том 17, № 3 (2021); 29 ; Онкоурология; Том 17, № 3 (2021); 29 ; 1996-1812 ; 1726-9776
Subject Terms: опухолевоспецифическая выживаемость, опухолевый венозный тромбоз, забрюшинная лимфаденэктомия, циторедуктивная нефрэктомия
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1498/1295; https://oncourology.abvpress.ru/oncur/article/view/1498
-
8Academic Journal
Authors: Д. А. Носов, Б. Я. Алексеев, М. И. Волкова, О. А. Гладков, А. М. Попов, Г. Ю. Харкевич
Source: Malignant tumours; Том 10, № 3s2-1 (2020); 533-541 ; Злокачественные опухоли; Том 10, № 3s2-1 (2020); 533-541 ; 2587-6813 ; 2224-5057
Subject Terms: циторедуктивная нефрэктомия, иммунотерапия, ингибиторы m-TOR, ингибиторы VEGFR
File Description: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/780/544; https://www.malignanttumors.org/jour/article/view/780
-
9Academic Journal
Authors: Pasichnyk, S. M., Dmytriv, V. J., Borys, Yu. B.
Source: Bulletin of Scientific Research; No 3 (2017) ; Вестник научных исследований; № 3 (2017) ; Вісник наукових досліджень; № 3 (2017) ; 2415-8798 ; 1681-276X ; 10.11603/2415-8798.2017.3
Subject Terms: kidney cancer, chronic kidney disease, radical nephrectomy, cytoreductive nephrectomy, рак почки, хроническая болезнь почек, радикальная нефрэктомия, циторедуктивная нефрэктомия, рак нирки, хронічна хвороба нирок, радикальна нефректомія, циторедуктивна нефректомія
File Description: application/pdf
Relation: https://ojs.tdmu.edu.ua/index.php/visnyk-nauk-dos/article/view/8088/7593; https://repository.tdmu.edu.ua//handle/123456789/12489
-
10Academic Journal
Authors: О. I. Evsyukova, V. В. Matveev, О. И. Евсюкова, В. Б. Матвеев
Source: Cancer Urology; Том 15, № 4 (2019); 120-125 ; Онкоурология; Том 15, № 4 (2019); 120-125 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2019-15-4
Subject Terms: иммунотерапия, cytoreductive nephrectomy, metastasectomy, targeted therapy, immunotherapy, циторедуктивная нефрэктомия, метастазэктомия, таргетная терапия
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1009/904; Аксель Е.М., Матвеев В.Б. Статистика злокачественных новообразований мочевых и мужских половых органов в России и странах бывшего СССР. Онкоурология 2019;15(2):15‒24. DOI:10.17650/1726-9776-2019-15-2-15-24.; Ljungberg B., Albiges L., Bensalah K. et al. EAU Guidelines on Renal Cell Carcinoma. European Association of Urology 2019. р. 5.2.2.; Campbell S.P., Baras A.S., Ball M.W. et al. Low levels of PSMA expression limit the utility of F-18-DCFPyL PET/CT for imaging urothelial carcinoma. Ann Nucl Med 2018;32:69–74. DOI:10.1007/s12149-017-1216-x.; Baccala A., Sercia L., Li J. et al. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology 2007;70(2):385–90. DOI:10.1016/j.urology.2007.03.025.; Raveenthiran S., Esler R., Yaxley J., Kyle S. The use of 68Ga-PET/CT PSMA in the staging of primary and suspected recurrent renal cell carcinoma. Eur J Nucl Med Mol Imaging 2019;46(11):2280‒8. DOI:10.1007/s00259-019-04432-2.; Delahunt B., Dagher J., Egevad L. et al. Is the UICC/AJCC pT2 staging category for clear cell renal cell carcinoma meaningful? Am J Surg Pathol 2019;43(9):1249‒52. DOI:10.1097/PAS.0000000000001308.; Tan W.S., Berg S., Cole A. et al. Comparing long-term outcomes following radical and partial nephrectomy for cT1 renal cell carcinoma in young and healthy individuals. Eur Urol Suppl 2019;18(1):1423–4. DOI:10.1016/s15699056(19)31027-9.; Pecoraro A., Palumbo C., Knipper S. et al. Cryoablation predisposes to higher cancer specific mortality relative to partial nephrectomy in patients with nonmetastatic pt1b kidney сancer. J Urol 2019;202(6):1120‒6. DOI:10.1097/JU.0000000000000460.; Guo S., Yao K., He X. et al. Prognostic significance of laterality in renal cell carcinoma: A population-based study from the surveillance, epidemiology, and end results (SEER) database. Cancer Med 2019;8(12). DOI:10.1002/cam4.2484.; Kaag M.G., Toyen C., Russo P. et al. Radical nephrectomy with vena caval thrombectomy: a contemporary experience. BJU Int 2010;107(9): 1386–93. DOI:10.1111/j.1464410x.2010.09661.x.; Freifeld Y., Woldu S.L., Singla N. et al. Impact of hospital case volume on outcomes following radical nephrectomy and inferior vena cava thrombectomy. Eur Urol Oncol 2019;2(6):691‒8. DOI:10.1016/j.euo.2018.10.005.; Serena G., Gonzalez J., Gaynor J.J. et al. Pulmonary tumor embolization as early manifestation in patients with renal cell carcinoma and tumor thrombus: Perioperative management and outcomes J Card Surg 2019;34(10):1018–23. DOI:10.1111/jocs.14182.; Méjean A., Ravaud A., Thezenas S. et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. NEJM 2018;379(5):417–27. DOI:10.1056/nejmoa1803675.; Méjean A., Thezenas S., Chevreau C. et al. Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): Update on CARMENA trial with focus on intermediate IMDC-risk population. J Clin Oncol 2019;37 Suppl. 15:4508. DOI:10.1200/JCO.2019.37.15_suppl.4508; Linehan W.M., Spellman P.T., Ricketts C.J. et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med 2016;374(2):135–45. DOI: 0.1056/NEJMoa1505917.; Graham J., Wells J.C., Donskov F. et al. Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma: results from the International metastatic renal cell carcinoma database consortium. Eur Urol Oncol 2019;2(6):643‒8. DOI:10.1016/j.euo.2019.03.007.; Gao J., Karam J.A., Tannir N.M. et al. A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy (Bx). J Clin Oncol 2019;37 Suppl. 15:4501. DOI:10.1200/JCO.2019.37.15_suppl.4501.; Lyon T.D., Thompson R.H., Shah P.H. et al. Complete surgical metastasectomy of renal cell carcinoma in the postcytokine era. J Urol 2019. DOI:10.1097/JU.0000000000000488.; Rini B.I., Plimack E.R., Stus V. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. NEJM 1–12 February 16, 2019. DOI:10.1056/NEJMoa1816714.; Rini B.I., Plimack E.R., Stus V. et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. J Clin Oncol 2019;37(15):4500. DOI:10.1200/JCO.2019.37.15_suppl.4500.; Motzer R.J., Tannir N.M., McDermott D.F. et al. Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018;378:1277–90. DOI:10.1016/j.eururo.2018.07.019.; McDermott D.F., Choueiri T.K., Motzer J.R. et al. CheckMate 214 posthoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features. J Clin Oncol 2019;37 Suppl. 15:4513. DOI:10.1200/JCO.2019.37.15_suppl.4513.; Tannir N.M., Arén F.O., Hammers H.J. et al. Thirty-month follow-up of the phase III CheckMate 214 trial of firstline nivolumab + ipilimumab (N + I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol 2019;37 Suppl. 7:547. DOI:10.1200/JCO.2019.37.7_suppl.547.; Rini B.I., Powles T., Atkins M.B. et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion 151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 2019;393(10189):2404‒15. DOI:10.1016/s0140-6736(19)30723-8.; Flaifel A., Xie W., Braun D.A. et al. PD-L1 expression and clinical outcomes to cabozantinib, everolimus and sunitinib in patients with metastatic renal cell carcinoma: analysis of the randomized clinical trials METEOR and CABOSUN. Clin Cancer Res 2019;25(20):1135. DOI:10.1158/10780432.ccr-19-1135.; Powles T., Larkin J.M.G., Patel P. et al. A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO). J Clin Oncol 2019;37 Suppl. 7:545. DOI:10.1200/JCO.2019.37.7_suppl.545.; Appleman L.J., Puligandla M., Pai S. et al. Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810). J Clin Oncol 2019;37 Suppl. 15:4502. DOI:10.1200/JCO.2019.37.15_suppl.4502.; Motzer R.J., Penkov K., Haanen J. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380(12):1103‒15. DOI:10.1056/NEJMoa1816047.; Choueiri T.K., Albiges L., Haanen J.B.A.G. et al. Biomarker analyses from JAVELIN Renal 101: avelumab + axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). J Clin Oncol 2019; 37 Suppl. 15:101. DOI:10.1200/ JCO.2019.37.15_suppl.101. DOI:10.17650/1726‑9776‑2019‑15‑4-120-125; https://oncourology.abvpress.ru/oncur/article/view/1009
-
11Academic Journal
Authors: M. I. Volkova, М. И. Волкова
Source: Malignant tumours; Том 8, № 4 (2018); 26-29 ; Злокачественные опухоли; Том 8, № 4 (2018); 26-29 ; 2587-6813 ; 2224-5057
Subject Terms: исследование CARMENA, cytoreductive nephrectomy, CARMENA study, циторедуктивная нефрэктомия
File Description: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/588/408; Flanigan R.C., Salmon S.E., Blumenstein B.A. et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. 2001. Vol. 345. P. 1655–1659.; Mickisch G.H., Garin A., van Poppel H., de Prijck L., Sylvester R. European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001. Vol. 358. P. 966–970.; Hanna N., Sun M., Meyer C.P. et al. Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study. J. Clin. Oncol. 2016. Vol. 34(27). P. 3267–75.; Heng D.Y., Wells J.C., Rini B. et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur. Urol. 2014. Vol. 66(4). P. 704–710.; Mejean A., Ravaud A., Thezenas S. et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. N. Engl. J. Med. 2018. Vol. 379. P. 417–427.; Motzer R.J., Mazumdar M., Bacik J., Berg W., Amsterdam A., Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 1999. Vol. 17. P. 2530–40.; Barbastefano J., Garcia J.A., Elson P. et al. Association of percentage of tumour burden removed with debulking nephrectomy and progression free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor targeted therapy. BJU International. 2010. Vol. 106. Issue 9. P. 1266–1269.; Motzer R.J., Tannir N.M., McDermott D.F. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N. Engl. J. Med. 2018. Vol. 378(14). P. 1277–1290.; Choueiri T.K., Halabi S., Sanford B.L. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. J. Clin. Oncol. 2017. Vol. 35(6). P. 591–597.; Manley B., Tennenbaum D.M., Vertosick E.A. et al. The Difficulty in Selecting Patients for Cytoreductive Nephrectomy: An Evaluation of Previously Described Predictive Models. J. Urol. Oncol. 2017. Vol. 35(1). P. 35.e1–35.e5.; Климов А.В., Волкова М.И., Широкорад В.И., Калинин С.А., Петерс М.В., Матвеев В.Б. Паллиативная нефрэктомия до таргетной терапии у больных диссеминированным раком почки // Онкоурология. 2015. Т. 11(3). С. 24–33.; https://www.malignanttumors.org/jour/article/view/588
-
12Academic Journal
Authors: V. B. Matveev, A. S. Markova, В. Б. Матвеев, А. С. Маркова
Source: Cancer Urology; Том 14, № 4 (2018); 48-52 ; Онкоурология; Том 14, № 4 (2018); 48-52 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2018-14-4
Subject Terms: индекс массы тела, kidney resection, kidney biopsy, cytoreductive nephrectomy, targeted therapy, immunotherapy, body mass index, резекция почки, биопсия почки, циторедуктивная нефрэктомия, таргетная терапия, иммунотерапия
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/899/807; Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68(1):7—30. DOI:10.3322/caac.21442. PMID: 29313949.; Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018. 250 с.; Состояние онкологической помощи населению России в 2017 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018. 236 с.; Ljungberg B., Albiges L., Bensalah K. et al. EAU Guidelines on Renal Cell Car-cinoma. European Association of Urology 2018. Pp. 1—70.; Marconi L., Dabestani S., Lam T.B. et al. Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy. Eur Urol 2016;69(4): 660—73. DOI:10.1016/j.eururo.2015.07.072. PMID: 26323946.; Patel R.M., Safiullah S., Okhunov Z. et al. Pretreatment diagnosis of the small renal mass: status of renal biopsy in the United States of America. J Endourol 2018;32(9):884—90. DOI:10.1089/end.2018.0175. PMID: 29978713.; Chandrasekar T., Ahmad A.E., Fadaak K. et al. Natural history of complex renal cysts: clinical evidence supporting active surveillance. J Urol 2018;199(3):633—40. DOI:10.1016/j.juro.2017.09.078. PMID: 28941915.; Ristau B.T., Handorf E.A., Cahn D.B. et al. Partial nephrectomy is not associated with an overall survival advantage over radical nephrectomy in elderly patients with stage Ib—II renal masses: An analysis of the national cancer data base. Cancer 2018;124(19):3839—48. DOI:10.1002/cncr.31582. PMID: 30207380.; Antonelli A., Minervini A., Sandri M. et al. Below safety limits, every unit of glomerular filtration rate counts: assessing the relationship between renal function and cancer-specific mortality in renal cell carcinoma. Eur Urol 2018;74(5):661 —7. DOI:10.1016/j.eururo.2018.07.029. PMID: 30104082.; Janssen M.WW, Linxweiler J., Terwey S. et al. Survival outcomes in patients with large (>7cm) clear cell renal cell carcinomas treated with nephron-sparing surgery versus radical nephrectomy: Results of a multicenter cohort with long-term follow-up. PLoS One 2018;13(5):e0196427. DOI:10.1371/journal.pone.0196427. PMID: 29723225.; Goebell PJ., Muller L., Hubner A. et al. Body mass index as independent predictor of overall survival in patients with advanced renal cell carcinoma at start of systemic treatment — Analyses from the German clinical RCC-Registry. Urol Oncol 2018;36(10):470.e1—9. DOI:10.1016/j.urolonc.2018.07.007. PMID: 30131294.; Escudier B., Porta C., Schmidinger M. et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27(Suppl 5):v58—68. DOI:10.1093/annonc/mdw328. PMID: 27664262.; Flanigan R.C., Salmon S.E., Blumenstein B.A. et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345(23):1655—9. DOI:10.1056/NEJMoa003013. PMID: 11759643.; Mickisch G.H., Garin A., van Poppel H. et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358(9286):966—70. PMID: 11583750.; Motzer R.J., Mazumdar M., Bacik J. et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17(8): 2530-40. DOI:10.1200/JCO.1999.17.8.2530. PMID: 10561319.; Bex A., Mulders P., Jewett M. et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial. JAMA Oncol 2018. DOI:10.1001/jamaoncol.2018.5543. PMID: 30543350.; Woldu S.L., Matulay J.T., Clinton T.N. et al. Incidence and outcomes of delayed targeted therapy after cytoreductive nephrectomy for metastatic renal-cell carcinoma: a nationwide cancer registry study. Clin Genitourin Cancer 2018;16(6):e1221—35. DOI:10.1016/j.clgc.2018.08.001. PMID: 30217763.; Mejean A., Ravaud A., Thezenas S. et al. Sunitinib Alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med 2018;379(5):417—27. DOI:10.1056/NEJMoa1803675.; NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)/Kidney Cancer. Version 2.2019. September 17, 2018. Available at: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf.; Chen Y.W., Ornstein M.C., Wood L.S. et al. The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era. Urol Oncol 2018;36(10):470.e19—29. DOI:10.1016/j.urolonc.2018.06.013. PMID: 30131292.; Procopio G., Cognetti F., Miceli R. et al. A randomized, open label, multicenter phase 2 study, to evaluate the efficacy of sorafenib (So) in patients (pts) with metastatic renal cell carcinoma (mRCC) after a radical resection of the metastases: RESORT trial. J Clin Oncol 2018;36(15):4502.; McDermott D.F., Lee J.L., Szczylik C. et al. Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427. J Clin Oncol 2018;36(15):4500. DOI:10.1200/JCO.2018.36.15_suppl.4500.; Motzer R.J., Powles Th., Atkins M.B. et al. IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated meta-static renal cell carcinoma (mRCC). J Clin Oncol 2018;36(6):578.; Motzer R.J., Penkov K., Haanen J.B.A.G. et al. JAVELIN renal 101: a randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). Annals Oncol 2018;29(Suppl 8). Available at: https://doi.org/10.1093/annonc/mdy424.036.; https://oncourology.abvpress.ru/oncur/article/view/899
-
13Academic Journal
Authors: B. Ya. Alekseev, K. M. Nyushko, A. S. Kalpinsky, Б. Я. Алексеев, К. М. Нюшко, А. С. Калпинский
Source: Cancer Urology; Том 11, № 2 (2015); 23-33 ; Онкоурология; Том 11, № 2 (2015); 23-33 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2015-11-2
Subject Terms: неоадъювантная таргетная терапия, metastatic renal cell carcinoma, cytoreductive nephrectomy, radical nephrectomy, targeted therapy, sorafenib, sunitinib, bevacizumab, axitinib, pazopanib, neoadjuvant targeted therapy, метастатический почечно-клеточный рак, циторедуктивная нефрэктомия, радикальная нефрэктомия, таргетная терапия, сорафениб, сунитиниб, бевацизумаб, акситиниб, пазопаниб
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/450/433; International Agency for Research on Cancer. The GLOBOCAN project: cancer incidence and mortality worldwide in 2012. Доступно по адресу: http://globocan.iarc.fr/; Злокачественные новообразования в России в 2013 году: заболеваемость и смертность. Под ред. А. Д. Каприна, В. В. Старинского, Г. В. Петровой. М., 2015. [Malignant neoplasms in Russia in 2013: morbidity and mortality. Ed. A. D. Caprin, V. V. Starinskiy, G. V. Petrova. Moscow, 2015. (In Russ.)].; Flanigan R.C., Yonover P.M. The role of radical nephrectomy in metastatic renal cell carcinoma. Semin Urol Oncol ;19(2):98–102.; Bex A., Powles T. Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when. Expert Rev. Anticancer Ther 2012; 12(6):787–97.; Flanigan R. C., Salmon S. E., Blumenstein B. A. et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renalcell cancer. N Engl J Med 2001;345(23):1655–9.; Mickisch G. H., Garin A., Van Poppel H. et al. Radical nephrectomy plus interferonalfa- based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358(9286):966–70.; Flanigan R. C., Mickisch G., Sylvester R. et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171:1071–6.; Motzer R. J., Bukowski R. M., Figlin R. A. et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 2008;113(7): 1552–8.; Wood C. G. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Clin Cancer Res 2001; 13(2 Pt 2):697–702.; Zini L., Capitanio U., Perrotte P. et al. Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. Urology 2009;73(2): 342–6.; Choueiri T. K., Xie W., Kollmannsberger C. et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 2011;185(1):60–6.; Warren M., Venner P. M., North S. et al. A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment. Can Urol Assoc J 2001;3(4):281–9.; Aben K. K., Heskamp S., Janssen-Heijnen M. L. et al. Better survival in patients with metastasised kidney cancer after nephrectomy: a population-based study in the Netherlands. Eur J Cancer 2011;47(13):2023–32.; Kutikov A., Uzzo R. G., Caraway A. et al. Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU Int 2010;106(2):218–23.; Abdollah F., Sun M., Thuret R. et al. Mortality and morbidity after cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based study. Ann Surg Oncol 2011;18(10):2988–96.; Mizutani Y. Recent advances in molecular targeted therapy for metastatic renal cell carcinoma. Int J Urol 2009;16:444–8.; Sonpavde G., Sternberg C. N. Neoadjuvant systemic therapy for urological malignancies. BJU Int 2010;106:6–22.; Shuch B., Riggs S. B., LaRochelle J.C. et al. Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int 2008;102:692–6.; Schrader A. J., Steffens S., Schnoeller T. J. et al. Neoadjuvant therapy of renal cell carcinoma: A novel treatment option in the era of targeted therapy? Int J Urol 2012;19:903–7.; Silberstein J. L., Millard F., Mehrazin R. et al. Feasibility and efficacy of neoadjuvant sunitinib before nephron-sparing surgery. BJU Int 2010;106:1270–6.; Hellenthal N. J., Underwood W., Penetrante R. et al. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol 2010;184:859–64.; Bex A., van der Veldt A. A., Blank C. et al. Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery. World J Urol 2009;27:533–9.; Powles T., Kayani I., Blank C. et al. The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Ann Oncol 2011;22: 1041–7.; Margulis V., Matin S. F., Tannir N. et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 2008;180:94–8.; Chapin B. F., Delacroix S. E.Jr, Culp S. H. et al. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol 2011;60:964–71.; Wood C. G., Margulis V. Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease. Cancer 2009;115:2355–60.; Abel E. J., Culp S. H., Tannir N. M. et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 2011;59:10–5.; Harshman L. C., Yu R. J., Allen G. I. et al. Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC). Urol Oncol 2011.; Karakiewicz P. I., Suardi N., Jeldres C. et al. Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol 2008;53:845–8.; Di Silverio F., Sciarra A., Parente U. et al. Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy. Urol. Int. 2008;80: 451–3.; Kondo T., Hashimoto Y., Kobayashi H. et al. Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects. Jpn J Clin Oncol 2010;40:1173–9.; Harshman L. C., Srinivas S., Kamaya A., Chung B. I. Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib. Nat Rev Urol 2009;6:338–43.; Robert G., Gabbay G., Bram R. et al. Case study of the month. Complete histologic remission after sunitinib neoadjuvant therapy in T3b renal cell carcinoma. Eur Urol 2009;55:1477–80.; Bex A., van der Veldt A. A., Blank C. et al. Progression of a caval vein thrombus in two patients with primary renal cell carcinoma ыon pretreatment with sunitinib. Acta Oncol 2010;49:520–3.; Cost N. G., Delacroix S. E.Jr, Sleeper J. P. et al. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol 2011;59:912–8.; Cowey C. L., Amin C., Pruthi R. S. et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol 2010;28:1502–7.; Thomas A. A., Rini B. I., Stephenson A. J. et al. Surgical resection of renal cell carcinoma after targeted therapy. J Urol 2009;182(3):881–6.; Amin C., Wallen E., Pruthi R. S. et al. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology 2008;72(4):864–8.; Jonasch E., Wood C. G., Matin S. F. et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27:4076–81.; Powles T., Sarwar N., Stockdale A. et al. Pazopanib prior to planned nephrectomy in metastatic clear cell renal cancer: A clinical and biomarker study. J Clin Oncol 2013;31 (suppl; abstr 4508).; Rini B. I., Plimack E. R., Takagi T. et al. A phase ii study of pazopanib in patients with localized renal cell carcinoma to optimize preservation of renal parenchyma. J Urol 2015 Mar 23. pii: S0022–5347(15) 03398–4.; Alvarez A. L., Plimack E. R., Dreicer R. et al. A phase II study of pazopanib in patients with localized renal cell carcinoma to enable partial nephrectomy. J Clin Oncol 2014;32:5 (suppl; abstr 4522).; Karam J. A., Devine C. E., Urbauer D. L. et al. Phase II trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. J Clin Oncol (Meeting Abstracts) 2014;32:441.; Lane B. R., Derweesh I. H., Kim H. L. et al. Presurgical sunitinib reduces tumor size and may facilitate partial nephrectomy in patients with renal cell carcinoma. Urol Oncol 2015;33(3):112. e15–21.; https://oncourology.abvpress.ru/oncur/article/view/450
-
14Academic Journal
Authors: АЛЕКСЕЕВ Б.Я., НЮШКО К.М., КАЛПИНСКИЙ А.С.
File Description: text/html
-
15Academic Journal
Source: Онкоурология.
Subject Terms: ПОЧЕЧНО-КЛЕТОЧНЫЙ РАК,МЕТАСТАТИЧЕСКИЙ ПОЧЕЧНО-КЛЕТОЧНЫЙ РАК,ЦИТОРЕДУКТИВНАЯ НЕФРЭКТОМИЯ,РАДИКАЛЬНАЯ НЕФРЭКТОМИЯ,ТАРГЕТНАЯ ТЕРАПИЯ,СОРАФЕНИБ,СУНИТИНИБ,БЕВАЦИЗУМАБ,АКСИТИНИБ,ПАЗОПАНИБ,НЕОАДЪЮВАНТНАЯ ТАРГЕТНАЯ ТЕРАПИЯ, 03 medical and health sciences, 0302 clinical medicine, 3. Good health
File Description: text/html
